| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ... New England Journal of Medicine 348 (11), 994-1004, 2003 | 4044 | 2003 |
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 3849 | 2006 |
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood 122 (6), 872-884, 2013 | 1966 | 2013 |
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop … FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet, F Nicolini, L Legros, ... The lancet oncology 11 (11), 1029-1035, 2010 | 1375 | 2010 |
| Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study S Castaigne, C Pautas, C Terré, E Raffoux, D Bordessoule, JN Bastie, ... The Lancet 379 (9825), 1508-1516, 2012 | 685 | 2012 |
| Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials N Boissel, MF Auclerc, V Lhéritier, Y Perel, X Thomas, T Leblanc, ... Journal of Clinical Oncology 21 (5), 774-780, 2003 | 648 | 2003 |
| Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years P Rousselot, F Huguet, D Rea, L Legros, JM Cayuela, O Maarek, ... Blood 109 (1), 58-60, 2007 | 616 | 2007 |
| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis J Cortes, P Rousselot, DW Kim, E Ritchie, N Hamerschlak, S Coutre, ... Blood 109 (8), 3207-3213, 2007 | 539 | 2007 |
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial H Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ... Blood, The Journal of the American Society of Hematology 109 (12), 5143-5150, 2007 | 498 | 2007 |
| Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia C Preudhomme, J Guilhot, FE Nicolini, A Guerci-Bresler, F Rigal-Huguet, ... New England Journal of Medicine 363 (26), 2511-2521, 2010 | 417 | 2010 |
| Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH … A de Labarthe, P Rousselot, F Huguet-Rigal, E Delabesse, F Witz, ... Blood 109 (4), 1408-1413, 2007 | 384 | 2007 |
| Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation R Nasr, MC Guillemin, O Ferhi, H Soilihi, L Peres, C Berthier, P Rousselot, ... Nature medicine 14 (12), 1333-1342, 2008 | 366 | 2008 |
| Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped … P Rousselot, A Charbonnier, P Cony-Makhoul, P Agape, FE Nicolini, ... Journal of clinical oncology 32 (5), 424-430, 2014 | 338 | 2014 |
| Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients P Rousselot, S Labaume, JP Marolleau, J Larghero, MH Noguera, ... Cancer research 59 (5), 1041-1048, 1999 | 293 | 1999 |
| Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic … NP Shah, DW Kim, H Kantarjian, P Rousselot, PED Llacer, A Enrico, ... haematologica 95 (2), 232-240, 2010 | 292 | 2010 |
| Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients C Alberti, A Bouakline, P Ribaud, C Lacroix, P Rousselot, T Leblanc, ... Journal of hospital infection 48 (3), 198-206, 2001 | 279 | 2001 |
| Expression and prognostic significance of survivin in de novo acute myeloid leukaemia C Adida, C Recher, E Raffoux, MT Daniel, AL Taksin, P Rousselot, ... British journal of haematology 111 (1), 196-203, 2000 | 279 | 2000 |
| Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia G Etienne, J Guilhot, D Rea, F Rigal-Huguet, F Nicolini, A Charbonnier, ... Journal of Clinical Oncology 35 (3), 298-305, 2017 | 258 | 2017 |
| High molecular response rate of polycythemia vera patients treated with pegylated interferon α–2a JJ Kiladjian, B Cassinat, P Turlure, N Cambier, M Roussel, S Bellucci, ... Blood 108 (6), 2037-2040, 2006 | 257 | 2006 |
| Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi (ϕ … FE Nicolini, S Corm, QH Le, N Sorel, S Hayette, D Bories, T Leguay, ... Leukemia 20 (6), 1061-1066, 2006 | 253 | 2006 |
